Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma

• Published in: Heliyon Vol. 9; no. 6; p. e17399
• Main Authors: Boboila, Shuobo, Okochi, Shunpei, Banerjee, Debarshi, Barton, Sunjay, Street, Cherease, Zenilman, Ariela L., Wang, Qi, Gartrell, Robyn D., Saenger, Yvonne M., Welch, David, Wu, Cheng-Chia, Kadenhe-Chiweshe, Angela, Yamashiro, Darrell J., Connolly, Eileen P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2023; Elsevier
• Subjects: Cancer therapeutics; Combination therapy; High dose radiation therapy; Immunotherapy; MYCN-amplified neuroblastoma; Neuroblastoma; Novel syngeneic mouse model; MYCN-amplified neuroblastoma; Cancer therapeutics; Novel syngeneic mouse model; Immunotherapy; Neuroblastoma; High dose radiation therapy; Combination therapy

The mortality in patients with MYCN-amplified high-risk neuroblastoma remains greater than 50% despite advances in multimodal therapy. Novel therapies are urgently needed that requires preclinical evaluation in appropriate mice models. Combinatorial treatment with high-dose radiotherapy (HDRT) and i...